Latest Innovation News

Westpac reported a resilient full-year 2025 performance with modest profit decline, robust loan and deposit growth, and ongoing strategic initiatives aimed at simplifying operations and enhancing customer experience.

Westpac Banking Corporation reported a slight 1% decline in net profit to $6.916 billion for 2025, while maintaining a strong capital position and progressing its UNITE transformation program. The bank declared a fully franked final dividend of 77 cents per share, underscoring its commitment to shareholder returns amid ongoing economic challenges.

Skin Elements Limited reports successful completion of key product evaluations and secures $2.5 million placement to fuel growth and commercialisation in 2026.

4DS Memory Limited reveals a pivotal quarter marked by a strategic review, executive departures, and a contentious board nomination ahead of its AGM.

ClearVue Technologies has secured a $4.6 million capital raise and signed major partnerships, setting the stage for commercialisation in 2026 with a robust $60 million project pipeline.

Tinybeans Group Limited reports steady subscription revenue and improved cash flow in Q1 FY26, while launching a new iOS Photo Store to diversify income streams and enhance user monetisation.

Tryptamine Therapeutics has initiated the world’s first clinical trial of its IV-infused psilocin drug, TRP-8803, targeting Binge Eating Disorder, alongside a pioneering EEG biomarker collaboration and new funding.

Pointerra Limited reported a stronger Q1 FY26 with nearly A$2 million in customer receipts and advancing AI-powered digital twin solutions across key sectors, setting the stage for improved cash flow and expanded market presence.

Tartana Minerals reports a significant new gold resource estimate at Cardross alongside robust copper sulphate sales and strategic board changes, positioning itself as a rising copper-gold producer in Far North Queensland.

DTI Group secures a major $2 million contract with Rio Tinto for autonomous locomotive tech and re-enters the European market through a new agreement with CAF.

Recce Pharmaceuticals has commenced patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, supported by promising antibacterial efficacy data and extended funding arrangements.

InFocus Group Holdings has launched two new strategic units targeting digital assets and iGaming, backed by a significant loan and guided by a newly formed advisory board featuring industry veterans.